Incyte Corporation Share Price & Technical Analysis
INCY · $97.16 (-0.26%)
Healthcare / Biotechnology
$97.16
-0.26%
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chro…
Price chart
Seasonality
May has 4 positive and 1 negative years (last 5 years shown)
2% return in May, 0% avg return in past 3 year May month.
0% return in 2026, 11% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 2% | 2% | -6% | 1% | 2% | – | – | – | – | – | – | – | 0% |
| 25 | 6% | 0% | -18% | 4% | 5% | 5% | 11% | 13% | 0% | 10% | 11% | -5% | 44% |
| 24 | -6% | 0% | -3% | -9% | 11% | 5% | 8% | 1% | 0% | 11% | 1% | -7% | 13% |
| 23 | 6% | -9% | -6% | 3% | -18% | 1% | 2% | -2% | -11% | -6% | 1% | 15% | -23% |
| 22 | 2% | -8% | 17% | -6% | 2% | 0% | 3% | -9% | -5% | 11% | 6% | 0% | 11% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Uptrend
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$19.93B
P/E ratio
14.09
52W high
$112.3
52W low
$63.51
Volume
8,55,496
Beta
0.80
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Incyte Corporation share price today?
- Incyte Corporation (INCY) last traded around $97.16 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does INCY have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for INCY. Download the app for real-time alerts.
- How can I analyze Incyte Corporation stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.